Informační systém MU
PAGANO, L., J. SALMANTON-GARCIA, F. MARCHESI, A. BUSCA, P. CORRADINI, M. HOENIGL, N. KLIMKO, P. KOEHLER, A. PAGLIUCA, F. PASSAMONTI, L. VERGA, B. VISEK, O. ILHAN, G. NADALI, Barbora WEINBERGEROVÁ, R. CORDOBA-MASCUNANO, M. MARCHETTI, G. P. COLLINS, F. FARINA, C. CATTANEO, A. CABIRTA, M. GOMES-SILVA, F. ITRI, J. VAN DOESUM, M. P. LEDOUX, M. CERNAN, O. JAKSIC, R. F. DUARTE, G. MAGLIANO, A. S. OMRANI, N. S. FRACCHIOLLA, A. KULASEKARARAJ, T. VALKOVIC, C. B. POULSEN, M. MACHADO, A. GLENTHOJ, I. STOMA, Zdenek RACIL, K. PIUKOVICS, Milan NAVRATIL, Z. EMARAH, U. SILI, J. MAERTENS, O. BLENNOW, R. BERGANTIM, C. GARCIA-VIDAL, L. PREZIOSO, A. GUIDETTI, M. I. DEL PRINCIPE, M. POPOVA, N. DE JONGE, I. ORMAZABAL-VELEZ, N. FERNANDEZ, I. FALCES-ROMERO, A. CUCCARO, S. MEERS, C. BUQUICCHIO, D. ANTIC, M. AL-KHABORI, R. GARCIA-SANZ, M. M. BIERNAT, M. C. TISI, E. SAL, L. RAHIMLI, N. COLOVIC, M. SCHONLEIN, M. CALBACHO, C. TASCINI, C. MIRANDA-CASTILLO, N. KHANNA, G. A. MENDEZ, V. PETZER, J. NOVAK, C. BESSON, R. DULERY, S. LAMURE, M. NUCCI, G. ZAMBROTTA, Pavel ZAK, G. C. SEVAL, V. BONUOMO, Jiří MAYER, A. LOPEZ-GARCIA, M. V. SACCHI, S. BOOTH, F. CICERI, M. OBERTI, M. SALVINI, M. IZUZQUIZA, R. NUNES-RODRIGUES, E. AMMATUNA, Ales OBR, R. HERBRECHT, L. NUNEZ-MARTIN-BUITRAGO, V. MANCINI, H. SHWAYLIA, M. SCIUME, J. ESSAME, M. NYGAARD, J. BATINIC, Y. GONZAGA, I. REGALADO-ARTAMENDI, L. K. KARLSSON, M. SHAPETSKA, Michaela HANAKOVA, S. EL-ASHWAH, Z. BORBENYI, G. M. COLAK, A. NORDLANDER, G. DRAGONETTI, A. M. E. MARAGLINO, A. RINALDI, C. DE RAMON-SANCHEZ and O. A. CORNELY. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2021, vol. 14, No 1, p. 1-15. ISSN 1756-8722. Available from: https://dx.doi.org/10.1186/s13045-021-01177-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Authors PAGANO, L. (guarantor), J. SALMANTON-GARCIA, F. MARCHESI, A. BUSCA, P. CORRADINI, M. HOENIGL, N. KLIMKO, P. KOEHLER, A. PAGLIUCA, F. PASSAMONTI, L. VERGA, B. VISEK, O. ILHAN, G. NADALI, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), R. CORDOBA-MASCUNANO, M. MARCHETTI, G. P. COLLINS, F. FARINA, C. CATTANEO, A. CABIRTA, M. GOMES-SILVA, F. ITRI, J. VAN DOESUM, M. P. LEDOUX, M. CERNAN, O. JAKSIC, R. F. DUARTE, G. MAGLIANO, A. S. OMRANI, N. S. FRACCHIOLLA, A. KULASEKARARAJ, T. VALKOVIC, C. B. POULSEN, M. MACHADO, A. GLENTHOJ, I. STOMA, Zdenek RACIL (203 Czech Republic), K. PIUKOVICS, Milan NAVRATIL, Z. EMARAH, U. SILI, J. MAERTENS, O. BLENNOW, R. BERGANTIM, C. GARCIA-VIDAL, L. PREZIOSO, A. GUIDETTI, M. I. DEL PRINCIPE, M. POPOVA, N. DE JONGE, I. ORMAZABAL-VELEZ, N. FERNANDEZ, I. FALCES-ROMERO, A. CUCCARO, S. MEERS, C. BUQUICCHIO, D. ANTIC, M. AL-KHABORI, R. GARCIA-SANZ, M. M. BIERNAT, M. C. TISI, E. SAL, L. RAHIMLI, N. COLOVIC, M. SCHONLEIN, M. CALBACHO, C. TASCINI, C. MIRANDA-CASTILLO, N. KHANNA, G. A. MENDEZ, V. PETZER, J. NOVAK, C. BESSON, R. DULERY, S. LAMURE, M. NUCCI, G. ZAMBROTTA, Pavel ZAK (203 Czech Republic), G. C. SEVAL, V. BONUOMO, Jiří MAYER (203 Czech Republic, belonging to the institution), A. LOPEZ-GARCIA, M. V. SACCHI, S. BOOTH, F. CICERI, M. OBERTI, M. SALVINI, M. IZUZQUIZA, R. NUNES-RODRIGUES, E. AMMATUNA, Ales OBR (203 Czech Republic), R. HERBRECHT, L. NUNEZ-MARTIN-BUITRAGO, V. MANCINI, H. SHWAYLIA, M. SCIUME, J. ESSAME, M. NYGAARD, J. BATINIC, Y. GONZAGA, I. REGALADO-ARTAMENDI, L. K. KARLSSON, M. SHAPETSKA, Michaela HANAKOVA (203 Czech Republic), S. EL-ASHWAH, Z. BORBENYI, G. M. COLAK, A. NORDLANDER, G. DRAGONETTI, A. M. E. MARAGLINO, A. RINALDI, C. DE RAMON-SANCHEZ and O. A. CORNELY.
Edition JOURNAL OF HEMATOLOGY & ONCOLOGY, LONDON, BMC, 2021, 1756-8722.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 23.168
RIV identification code RIV/00216224:14110/21:00122744
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s13045-021-01177-0
UT WoS 000707341700001
Keywords in English COVID-19; Pandemic; Hematological malignancies; Epidemiology; EHA
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/11/2021 09:44.
Abstract
Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March-May 2020) and the second wave (October-December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.
Links
2015-1-CZ01-KA203-013935, interní kód MUName: Medical Curriculum Innovations (Acronym: MEDCIN)
Investor: European Union, Strategic Partnerships in the field of education, training and youth
Displayed: 25/8/2024 01:25